Martin Shkreli Is Shorting This ‘Strong Buy’ Penny Stock. How Should You Play Shares Here?
Martin Shkreli says aTyr stock could crash as much as 80% within the next six weeks. ATYR shares are not particularly attractive even without his warning.
| Ticker |
ATYR
|
| CIK | 0001339970 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
| Address | 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO, CA, 92121 |
| Website | atyrpharma.com |
| Phone | 8587318389 |
| CEO | Sanjay S. Shukla |
| Employees | 53 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Martin Shkreli Is Shorting This ‘Strong Buy’ Penny Stock. How Should You Play Shares Here?Martin Shkreli says aTyr stock could crash as much as 80% within the next six weeks. ATYR shares are not particularly attractive even without his warning. aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary SarcoidosisTopline results expected in the third quarter of 2025.SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the last patient has completed their last visit in the Company’s Phase 3 EFZO-FIT™ study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary s Favourable Signals For aTyr Pharma: Numerous Insiders Acquired StockWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... aTyr Pharma to be Added to the Russell 2000® and Russell 3000® IndexesSAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backingKey Insights Significantly high institutional ownership implies aTyr Pharma's stock price is sensitive to their trading... |